Navigation Links
High estrogen levels associated with dementia in older men

A prospective population-based study has found that higher estrogen levels in older men are associated with an increased risk of dementia. By contrast, levels of testosterone were not associated with cognitive decline. The study is in the August issue of Annals of Neurology, a journal published by John Wiley & Sons. (http://www.interscience.wiley.com/journal/ana).

As our population ages, the impact of dementia will grow. By the year 2050, some 13 million Americans could have Alzheimer's disease, which is the most common cause of dementia. Researchers are searching to understand risk factors and some studies have suggested that sex hormones play a role. One large study showed that women receiving estrogen therapy had an increased risk of cognitive impairment and dementia. However, the evidence for how testosterone levels affect men is contradictory.

To better understand the role of sex hormones in dementia, researchers led by Mirjam Geerlings, Ph.D. of the University Medical Center Utrecht, studied whether older men's levels of testosterone and estrogen were associated with their risk of cognitive decline and developing dementia, including Alzheimer's disease.

They examined data from the prospectively studied population-based cohort of 2974 Japanese-American men aged 70 to 91 who participated in the Honolulu-Asia Aging Study. Participants showed no signs of dementia at baseline in 1991-1993, at which time fasting blood samples were drawn. The researchers measured the levels of testosterone and estradiol, the major estrogen in humans, in the samples and the men were reexamined for evidence of cognitive decline or dementia in 1994-1996 and 1997-1999 using the Cognitive Abilities Screening Instrument (CASI). At each exam, researchers also collected physical, demographic and medical information.

A total of 2300 men completed the study and 223 were diagnosed with incident dementia during the follow-up period. 134 men developed Alzheimer's disease, and 44 developed vascular dementia. The researchers used Cox regression analyses, adjusting for age and other covariates, to see if hormone levels were associated with risk of developing dementia

"Levels of bioavailable testosterone were not associated with risk of cognitive decline and incident dementia," they report. "In contrast, higher levels of bioavailable estradiol were associated with an increased risk for cognitive decline and Alzheimer's disease." For each standard deviation increase in estradiol level, the risk for the disease went up by 25 percent. Furthermore, compared with the lowest tertile of estradiol, men in the middle and highest tertile had .24 and .28 points lower CASI scores, respectively, for each year increase in age.

The researchers hypothesize that the estradiol association could be explained by increased aromatase activity in the brain which may be associated with a neurodegenerative process. It is then possible that the high levels of estradiol are a consequence or early marker of Alzheimer's disease rather than a cause.

Some caution is needed when interpreting the results, as, due to death or refusal, some men could not be given a diagnosis of dementia or follow-up cognitive testing.

In conclusion, the authors report, "our findings of an increased risk of cognitive decline and Alzheimer's disease associated with higher estradiol are similar to recent findings in postmenopausal women. Further studies are needed to examine whether there are mechanisms by which estradiol may increase risk of cognitive decline and dementia."


'"/>

Source:John Wiley & Sons, Inc.


Related biology news :

1. Harmful chemicals may reprogram gene response to estrogen
2. Compounds in plastic packaging act as environmental estrogens altering breast genes
3. Tamoxifen-like drug suggests new ways to selectively block estrogen
4. Researchers uncover mechanisms of estrogen in promoting cell death in breast cancer
5. Ultra low-dose estrogen shown safe for post-menopausal women
6. New path from estrogen to survival in breast cancer cells described
7. Changing length of days reverses how estrogen affects aggressiveness in mice
8. Molecular atlas provides new tool for understanding estrogen-fueled breast cancer
9. New lab technique identifies high levels of pathogens in therapy pool
10. Scientists at Galileo Pharmaceuticals confirm inflammatory response linked to glucose levels
11. MERIS monitoring tracks planetary photosynthesis levels
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/26/2017)... DENVER , Jan. 26, 2017  Acuity ... Trends for Biometrics and Digital Identity".  Acuity characterizes ... digital identity when increased adoption reflects a new ... "Biometrics and digital identity are ... says Maxine Most , Principal of Acuity ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds ... baby,s sock that monitors vital signs and alerts ... an infant,s oxygen saturation level drops. But pediatric ... alarm to parents, with no evidence of medical ... devices are marketed aggressively to parents of healthy ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... -- Kurzlehrgang mit Fokus auf Assay ... legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen dar   ... ... Yoav Peretz , Scientific Director bei ImmuneCarta, einen Kurzlehrgang ... Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im Rahmen der ...
(Date:2/18/2017)... ... 2017 , ... A leader in science-based, age-fighting skincare products, ... is proud to introduce its Age-Defying Night Cream, NeriumAD™ Formula, Age-Defying Day Cream, ... Hong Kong. The luxury skincare products contain innovative ingredients that fight the signs ...
(Date:2/17/2017)... , February 17, 2017 ... Market by Product (Consumables, Service), Type (Safety, Efficacy, ... Development, Drug Discovery and Development, Disease-Risk) - Global ... is projected to reach USD 53.34 Billion by ... at a CAGR of 13.8% during the forecast ...
(Date:2/17/2017)... Mass. , Feb. 17, 2017  If ... small tumor had a mutation-conferring resistance to chemotherapy, ... Recently, genomics research has focused on finding these ... or even from circulating tumor DNA in blood ... new oncology therapeutics. Unfortunately, however, detecting ...
Breaking Biology Technology: